Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics, a clinical-stage cancer immunotherapy company. Dr. Liu is internationally known in the field of antibody engineering and therapeutics, and is the editor of Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development. He is a pioneer in the field of antibodies targeting intracellular cancer antigens, which BioCentury called a “Eureka moment for TCR mimics.” Dr. Liu holds more than 100 patents and has authored numerous peer-reviewed papers in the field of cancer immunotherapy. He is the inventor of multiple first-in-class cancer drugs, targeting CSF1 for treatment of bone metastasis, BCMA for multiple myeloma, and AFP and GPC3 for liver cancer, all currently in human clinical trials. Dr. Liu holds a BS in Cell Biology and Genetics from Beijing University and a PhD in Molecular Cell Biology from the University of California, Berkeley.